IGYXOS is a startup based in France. Brouky records 1 investor associated with the company.
IGYXOS develops monoclonal antibody therapeutics aimed at improving infertility treatment by enhancing the activity of Follicle Stimulating Hormone (FSH) to improve reproductive health outcomes for men and women.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.